Immatics
Immatics is seeking a strategic leader to establish and direct the IT Commercial & Patient Operations function, enabling the US commercial launch strategy and driving IT launch milestones. This role serves as the bridge between the US Commercial organization and global IT, translating functional needs into an executable technology portfolio. The position involves owning the end-to-end IT Commercial and Medical Affairs roadmap while managing dependencies across vendors, stakeholders, and global teams.
Headquarters
Tübingen, Baden-Württemberg, Germany
Company Size
201-500 employees
Founded
2000
Immatics is the global leader in precision targeting of PRAME, a cancer-associated antigen expressed in more than 50 cancer types. The company develops PRAME-targeted cell therapies (including TCR T-cell therapies) and TCR bispecific product candidates, with an active clinical pipeline spanning indications such as melanoma, lung, ovarian, breast, and endometrial cancers. Immatics combines deep expertise in immunology and drug development to advance novel treatments for patients with significant unmet medical need.
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
2 hours ago
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
4 days ago
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Immatics.
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)?
3 days ago